Despite considerable challenges, RNA interference (RNAi) as a therapeutic strategy continues to draw excitement and scrutiny. Two recent meetings—Select Biosciences’ “RNAi and miRNA World Congress” ...
Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...
The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...
Alnylam Pharmaceuticals and PeptiDream are partnering to develop a peptide-based delivery system for Alnylam’s small interfering RNA (siRNA) therapies that silence gene expression. Alnylam has three ...
Most siRNA oligonucleotides (oligos) for in vivo use are chemically synthesized duplexes of 21 to 23 oligos based on the original work of Tuschl and colleagues. 4, 5 Although chemical modifications ...
Despite the Nobel Prize-winning discovery of RNA interference (RNAi) over a decade ago and the billions of dollars spent developing therapeutic applications, delivery issues continue to challenge the ...
“The copious patentable aspects of a therapeutically efficacious siRNA delivery formulation imply intense patenting activity in the years to come, along with market exclusivity that can be extended ...
A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...
(RTTNews) - Avidity Biosciences, Inc. (RNA) reported positive AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial showing the first-ever successful targeted delivery of RNA ...
Welcome to the 3 rd Annual RNAi – Based Therapeutics Summit: Overcoming Barriers for Targeted siRNA Therapeutics Built with biopharmaceutical industry insights, this in person conference will bring ...
PeptiDream (TSE:4587) just logged two meaningful scientific wins, advancing an oral dual IL 17 program into its clinical portfolio and hitting a preclinical siRNA delivery milestone with Alnylam, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback